丹栀逍遥丸联合瑞舒伐他汀治疗非酒精性脂肪肝的疗效观察

目的探讨丹栀逍遥丸联合瑞舒伐他汀钙片治疗非酒精性脂肪肝的临床疗效。方法选取2014年11月—2016年12月襄阳市中心医院收治的非酒精性脂肪性肝病患者125例为研究对象,所有患者根据随机原则分为对照组(65例)和治疗组(60例)。对照组口服瑞舒伐他汀钙片,起始剂量10 mg/次,1次/d,治疗4周后根据血脂水平调整剂量,单日最大剂量不超过20 mg。治疗组在对照组的基础上口服丹栀逍遥丸,6 g/次,2次/d。28 d为1个疗程,两组患者治疗3个疗程后评价疗效。观察两组的临床疗效,比较两组的肝功能指标、血脂水平和肝脾电子计算机断层扫描(CT)比值。结果治疗后,对照组和治疗组的总有效率分别为84.62%、93.33%,两组比较差异具有统计学意义(P0.05)。治疗后,两组丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转氨酶(AST)、谷氨酰转肽酶(GGT)水平均明显下降,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组这些肝功能指标明显低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组总胆固醇(TC)、三酰甘油(TG)水平明显下降,高密度脂蛋白胆固醇(HDL-C)水平明显升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组这些血脂指标水平明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组肝脾CT比值明显升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组肝脾CT比值明显高于对照组,两组比较差异具有统计学意义(P0.05)。结论丹栀逍遥丸联合瑞舒伐他汀钙片能够协同治疗非酒精性脂肪性肝病,改善肝功能指标和血脂水平,减轻脂肪肝严重程度,具有一定的临床推广应用价值。

Clinical observation of Danzhi Xiaoyao Pills combined with rosuvastatin in treatment of nonalcoholic fatty liver

Objective To investigate the clinical effect of Danzhi Xiaoyao Pills combined with Rosuvastatin Calcium Tablets in treatment of nonalcoholic fatty liver. Methods Patients (125 cases) with nonalcoholic fatty liver in Xiangyang Central Hospital from November 2014 to December 2016 were randomly divided into the control group (65 cases) and the treatment group (60 cases). Patients in the control group were po administered with Rosuvastatin Calcium Tablets, 10 mg/time, once daily, after treatment for 4 weeks, the dose was adjusted according to the blood lipid level. The maximum dose was not more than 20 mg/d. Patients in the treatment group were po administered with Danzhi Xiaoyao Pills on the basis of the control group, 6 g/time, twice daily. One course of treatment was 28 d, and patients in two groups were treated for 3 courses. After treatment, the clinical efficacies were evaluated, and liver function indexes, blood lipid levels, and CT ratio of liver and spleen in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 84.62% and 93.33%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of ALT, AST, and GGT in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of TC and TG in two groups were significantly decreased, but the levels of HDL-C in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the CT ratio of liver and spleen in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the CT ratio of liver and spleen in the treatment group was significantly higher than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Danzhi Xiaoyao Pills combined with Rosuvastatin Calcium Tablets has clinical curative effect in treatment of nonalcoholic fatty liver, can improve liver function and blood lipid, reduce the severity of fatty liver, which has a certain clinical application value.